“Scoring” Savings From Obesity Drugs: CBO Points To Gap Between Categories In Rx Labels And Economic Impact
This article was originally published in The Pink Sheet Daily
Proposals to expand Medicare coverage to include obesity therapies are unlikely to be treated as cost-effective by CBO without significant new research on the long term impact of relatively modest changes in BMI. Advocates for coverage may need to focus on other arguments instead.
You may also be interested in...
Weighty Issues: GW Obesity Drug Outcomes Project Tests a Model for Patient Input in Drug Development
A stakeholder project on obesity treatment outcomes will complete its work this summer, setting the stage for FDA to rethink efficacy endpoints for weight loss drug development. The closed-door project is happening in parallel with public advisory committee discussions on pending applications and safety standards. One impact will be to shape more formal patient-centered drug development activities in years to come.
Obesity drugs are readying for round two at FDA. But if ever approved, given the airing of safety issues at advisory committee meetings, who would pay for them?
The prototypical US FDA advisory committee review of a pending new drug application has become something of an endangered species. A suddenly busy October and November agenda suggests that might be changing.